Harrow appoints new leadership at ImprimisRx to drive next phase of growth
- bancheta6
- Oct 8
- 1 min read
Nashville, TN, October 6, 2025 (Globe Newswire) -- Harrow (Nasdaq: HROW) announced leadership changes at its subsidiary ImprimisRx, naming Frank Mullery as Chief Executive Officer and Bridseida Cruz as Head of Quality. Mullery brings over 20 years of experience leading pharmaceutical operations, including senior roles at Sintetica US, STI Pharma, and Mylan, where he helped drive over $1 billion in sterile injectable revenue. Cruz, with 25 years in quality and operations, is recognized for successful FDA compliance programs and operational excellence in compounding and pharma manufacturing. CEO Mark L. Baum said the appointments align with Harrow’s vision to strengthen its position as a leading U.S. ophthalmic company.
Read full article here.
Comments